{"id":"evarrest-sealant-matrix","safety":{"commonSideEffects":[{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Infection at surgical site"},{"rate":null,"effect":"Seroma formation"},{"rate":null,"effect":"Hematoma"}]},"_chembl":{"chemblId":"CHEMBL4650407","moleculeType":"Unknown"},"_fixedAt":"2026-03-30T16:04:23.299789","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The sealant matrix works by delivering thrombin and fibrinogen directly to bleeding surfaces, where they interact to form a stable fibrin clot that adheres to tissue and controls bleeding. The fibrin matrix is gradually absorbed by the body as wound healing progresses. This topical approach provides local hemostasis without systemic absorption of the active components.","oneSentence":"EVARREST is a hemostatic sealant matrix that combines human thrombin and fibrinogen to form a biodegradable fibrin clot at the surgical site, promoting rapid hemostasis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:49.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemostasis during general, cardiac, and vascular surgery"},{"name":"Control of bleeding from surgical sites where standard hemostatic measures are ineffective or impractical"}]},"_fixedFields":["pubmed(3)"],"trialDetails":[{"nctId":"NCT02227992","phase":"PHASE3","title":"The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study","status":"COMPLETED","sponsor":"Ethicon, Inc.","startDate":"2014-07-01","conditions":"Hemorrhage, Soft Tissue Bleeding, Hepatic Parenchyma Bleeding","enrollment":40},{"nctId":"NCT01681030","phase":"PHASE2","title":"The Fibrin Pad Cardiovascular Study","status":"COMPLETED","sponsor":"Ethicon, Inc.","startDate":"2012-08-01","conditions":"Cardiovascular Disease","enrollment":42},{"nctId":"NCT02040428","phase":"PHASE3","title":"The Fibrin Pad CV Phase III Study","status":"COMPLETED","sponsor":"Ethicon, Inc.","startDate":"2014-01-01","conditions":"Cardiovascular Disease","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"recentPublications":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["EVARREST™ Fibrin Sealant Patch"],"phase":"phase_3","status":"active","brandName":"EVARREST™ Sealant Matrix","genericName":"EVARREST™ Sealant Matrix","companyName":"Ethicon, Inc.","companyId":"ethicon-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"EVARREST™ Sealant Matrix is a topical hemostat used as an adjunct to hemostasis during cardiovascular surgery, and it has also been studied for its effectiveness in treating hemorrhage, soft tissue bleeding, and hepatic parenchyma bleeding. The exact mechanism of EVARREST™ is unknown, but it is classified as a fibrin sealant patch.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}